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Abstract: Several large statin trials and meta-analyses have demonstrated a reduction in 
low-density lipoprotein cholesterol (LDL-C) and cardiovascular morbidity and mortality. Some 
trials have also highlighted the significance of residual cardiovascular risk after treatment of 
LDL-C to target levels. This reflects the complex nature of residual cardiovascular risk. This 
residual risk is partially due to low HDL-C and high triglycerides (TG) despite achievement 
of LDL goals with statin therapy. The NCEP ATP III guidelines reported that low HDL-C is a 
significant and an independent risk factor for coronary heart disease (CHD) and is inversely 
related to CHD. Epidemiologic studies have also shown a similar inverse relationship of 
HDL-C with CHD. High-density lipoprotein cholesterol (HDL-C) may directly participate in 
the anti-atherogenic process by promoting efflux of cholesterol of the foam cells of atherogenic 
lesions. Many studies have demonstrated multiple anti-atherogenic actions of HDL-C and its 
role in promoting efflux of cholesterol from the foam cells. The residual risk by increased TG 
with or without low HDL-C can be assessed by calculating non–HDL-C and a reduction in TG 
results in decreased CHD.
Keywords: low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, statins, 
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Background
Statin therapy has been shown to lower the cardiovascular morbidity and mortality 
in virtually every population study. Several large trials and meta-analyses have 
consistently demonstrated that statins reduce low-density lipoprotein cholesterol 
(LDL-C) leading to a decrease in the incidence of cardiovascular events.1–6 Same statin-
trials also highlighted the significance of residual cardiovascular risk after treatment of 
LDL-C to target levels. Obviously all the residual cardiovascular risk is not modifiable 
because of age and gender issues. This residual cardiovascular risk is complex and is 
partially due to low high-density lipoprotein cholesterol (HDL-C) and high triglycerides 
(TG) despite achievement of LDL-C goals with statin therapy. The National Cholesterol 
Education Program (NCEP) ATP III guidelines reported that low HDL-C is a significant 
and independent risk factor for coronary heart disease (CHD)6 and is inversely related 
to CHD. The nature of the relationship between HDL-C and CHD is not clear. One 
theory is that HDL directly participates in the atherogenic process. Various studies 
have demonstrated multiple anti-atherogenic actions of HDL-C (Table 1).7 Studies in 
vitro have shown that HDL-C may promote efflux of cholesterol of the foam cells from 
atherogenic lesions, a process called reverse cholesterol transport. The residual risk by Vascular Health and Risk Management 2009:5 794
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increased TG with or without low HDL-C can be assessed by 
calculating non-HDL-C6 and modification in TG also result 
in decreased CHD.8
Residual CHD risk in patients 
treated with statins
A significant cardiovascular risk remains in statin-treated 
patients as shown in many trials. Although statins are 
very efficacious they do not eliminate the CHD risk 
associated with diabetes mellitus (DM).1,3,9–14 This residual 
cardiovascular risk issue in such populations was well 
illustrated by Cholesterol Treatment Trialists (CTT).15 In a 
meta-analysis of 90,056 patients, CTT collaborators found 
that residual CHD risk was particularly high in patients with 
statin monotherapy in 90,056 patients from 14 statin trials. 
This meta-analysis demonstrated the safety and efficacy 
of statin therapy in reducing 5-year incidence of major 
cardiovascular events (MACE). A reduction of 39 mg/dL of 
LDL-C was associated with a 20% decrease in the composite 
end point of non-fatal myocardial infarction (MI), coronary 
revascularization, and coronary death.15 This meta-analysis 
further confirmed a significant reduction in major vascular 
events with statin therapy in patients with and without DM. 
However, as revealed in this meta-analysis, CHD events are 
still higher in diabetic patients treated with statin than those 
patients without DM on placebo.15 This was demonstrated 
in the subgroup analysis of 18,686 patients with DM and 
71,370 without DM with mean follow up of 4.3 years.
Atherogenic dyslipidemia
Both DM and metabolic syndrome are associated with 
atherogenic dyslipidemia, which is characterized by 
high TG, elevated small dense LDL-C and low HDL-C. 
Such dyslipidemia confers a high risk of CHD on patients.16 
According to NCEP ATPIII, elevated TG is a marker for 
atherogenic remnant lipoproteins6 and the most readily 
available measure of this atherogenic remnant lipoprotein 
is very LDL (VLDL). A combination of both of these 
atherogenic lipoproteins (TG and VLDL) represents 
non-HDL-C. Furthermore, NCEP III guidelines state that 
non-HDL-C is calculated by subtracting HDL-C from 
total cholesterol and should be the secondary target if 
TG is 200 mg/dL. All three components of atherogenic 
dyslipidemia (LDL-C, HDL-C, and TG) are interrelated and 
each component predicts CHD risk.
Low-density lipoprotein cholesterol
It is not uncommon that LDL and LDL-C are used 
synonymously. LDL-C is a combination of lipoprotein 
(LDL) and lipid-like cholesterol. Cholesterol is packaged 
into lipoproteins in the form of cholesterol esters to make 
LDL-C. Lipoproteins differ in size and its cholesterol ester 
content. Therefore, small dense LDL particles can be more 
in number for the same level of blood cholesterol. The 
number of LDL-particles is an important predictor for risk 
from these lipoproteins when small LDL is present. The 
LDL-C value measured in a standard lipid profile does 
not provide information about the size of LDL particles. 
For example, a patient with normal LDL-C may have the 
majority of their cholesterol in small dense particles thus 
having more particles and placing the patient at higher risk 
for CHD.17
High-density lipoprotein cholesterol
HDL-C and HDL are not synonymous and a clear distinction 
should me made. HDL is a high-density lipoprotein which 
enables lipids like cholesterol to be transported back to liver. 
HDL-C represents HDL particle with cholesterol ester inside. 
Low HDL-C is another independent risk factor for CHD. 
It is a strong risk factor and is inversely associated with 
CHD risk.6 In an observational study, it was found to have 
a 2% to 3 % decrease in the risk of CHD for every 1 mg/dL 
increase in HDL.18 Another trial, Treating to New Targets 
(TNT), demonstrated a lower risk of CHD in groups with 
higher HDL.19 Although the mechanism is not clear, it is 
believed that the anti-atherogenic effect of HDL-C may be a 
result of reverse cholesterol transport (RCT), and anti-oxidant 
and anti-inflammatory properties.20 Furthermore, the size of 
HDL-C particles may also be important. The action of CETP 
(cholesterol ester transfer protein) plays an important role in 
determining the size of HDL-C particles. CETP is a plasma 
lipid transfer protein secreted by the liver. It facilitates the 
Table 1 The multiple anti-atherogenic actions of high-density 
lipoprotein cholesterol
1.  Reverse cholesterol transport
2.  Cellular cholesterol efflux
3. Anti-inflammatory action
4. Anti-infectious
5. Anti-oxidative
6. Anti-thrombotic
7. Anti-apoptotic
8.  endothelial repair
9. Vasodilatory activityVascular Health and Risk Management 2009:5 795
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exchange of TG from VLDL particle for cholesterol esters 
from HDL-C, resulting in smaller HDL-C particles. These 
resultant smaller HDL-C particles are readily cleared by the 
kidneys resulting in lower HDL-C particles.
Triglycerides
The independent prognostic value of TG was demonstrated 
in the Pravastatin or Atorvastatin Evaluation and Infectious 
Therapy-Thrombolysis in Myocardial infarction (PROVE 
IT-TIMI)-228 trial. This trial evaluated the role of intensive 
statin therapy in patients with acute coronary syndrome (ACS) 
admitted to hospital. After 2 years of follow up, significantly 
lower events occurred in patients with LDL-C  70 mg/dL. 
The relationship of LDL and TG to composite endpoints 
of CHD was assessed in this trial. After a multivariate 
adjustment, there were significantly fewer events in a 
treatment group with TG  150 mg/dL compared to the 
group with TG  150 mg/dL.8 Therefore, TG  150 mg/dL 
was associated with lower CHD risk independent of LDL-C 
level, and achieving both optimal LDL and TG may be an 
important strategy in ACS patients.
Treating beyond low-density 
lipoprotein cholesterol
According to NCEP and American Diabetes Association 
(ADA), LDL-C is the primary therapeutic target in lipid 
management. As described above, there are several other 
atherogenic particles which contribute to the CHD risk 
after LDL-goals are met. Therefore, non-HDL-C is a 
secondary therapeutic target.6,21 The American College 
of Cardiology (ACC) and ADA statement defines highest 
risk groups with known cardiovascular disease or patients 
without cardiovascular disease with DM associated with 
one or more risk factors such as smoking, hypertension, 
and family history of premature coronary artery dis-
ease (CAD). The 2008 ACC/ADA consensus statement 
sets specific lipid/lipoprotein goals based on cardiovas-
cular risk based on lipoprotein abnormalities and cardio-
metabolic risk. The goals for these highest risk patients are 
LDL-C  70 mg/dL, non-HDL-C  100 mg/dL, and apo-
lipoprotein B (Apo B) 80 mg/dL.22 Although statins are the 
initial drugs of choice, combination therapy may be needed 
as a strategy to meet lipid goals beyond just LDL-C target.
Modifying residual cardiovascular 
risk beyond LDL with statins
As discussed before, it is crucial to modify all the atherogenic 
risk factors for better outcomes in patients with atherosclerotic 
vascular disease. To modify the risk beyond statin therapy, 
the following drugs are available.
1.  Omega-3 fatty acids
2.  Niacin
3.  Fibrates
4.  Combination of statins with niacin
5.  Combination of statins with fibrates.
Omega-3 fatty acids
The 2007 National Lipid Associations (NLA) safety task 
force concluded that omega therapy is a safe therapeutic 
option for lowering TG.23 Observational studies have shown 
several cardiovascular benefits such as a decrease in cardiac 
dysrrythmias, sudden cardiac death, and a decrease in blood 
pressure.24 The mechanism of action of omega-3 fatty acids in 
the reduction of  TG is unclear. There is evidence that omega-3 
fatty acids increase TG clearance from circulating VLDL 
particles by increasing lipoprotein lipase (LPL) activity. 
Some studies have shown an increase of HDL-C with high 
doses of omega-3 fatty acids. In the JELIS study (Japan 
Epa Lipid Intervention Study), a combination of omega-3 
fatty acids and statin was compared with statin monotherapy. 
There was a 19% reduction in major coronary events by the 
combination therapy as compared to statin alone.25 Another 
trial, COMBOS (COMBination of prescription Omega-3 
plus Simvastatin) which also showed that a combination of 
omega-3 fatty acids and simvastatin reduced non-HDL-C, TG 
and raised HDL as compared to statin monotherapy.26 The 
AFFORD trial (Atorvastatin Factorial with Omega-3 fatty 
acids Risk Reduction in Diabetes)27 did not show any benefit 
of residual cardiovascular risk reduction in the diabetic 
population. It is important to note that dietary supplement 
of omega-3 fatty acids is not subject to FDA regulation and 
thus higher doses of fish oil supplement may be required to 
be equivalent to the prescription form of omega-3 fatty acids 
(Lovaga, previously called Omacor).23
Niacin
Niacin has long been recognized for its lipid-modifying 
effect. It has a well established safety profile based on clinical 
evidence over 20 years. This is the most effective agent in 
raising HDL-C and had been used for past 5 decades.28 
No major trials showed any potential interaction of niacin 
with statins. The Coronary Drug Project (CDP) was an 
outcome, randomized trial conducted between 1966 and 
1975 with a mean follow up of 6.2 years in men with history 
of previous MI.29 The primary end point of mortality did 
not decrease in the niacin group. However, a significant Vascular Health and Risk Management 2009:5 796
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reduction in composite outcome of CHD death, non-fatal MI, 
and cerebrovascular events occurred in this group. There was 
also a significant reduction of cardiovascular surgery ( 47%) 
in the niacin group.29,30 It should be added that 9 years after 
the termination of the trial, there was an 11% (P = 0.0004) 
mortality reduction in the niacin group compared to the 
placebo group.31
Niacin decreases hepatic synthesis of TG, leading to 
reduced synthesis of VLDL particles, and increased degra-
dation of APO-B and decreased catabolism of APO A.32,33 
Recent studies also indicate that it increase APO A-1, 
thereby increasing HDL-C.34 It may also enhance ABC A-1 
(ATP binding cassette) transporter transcription leading to 
HDL-mediated cholesterol efflux from peripheral cells.35
Compared to statins alone, combination therapy 
with niacin and statins has shown greater efficacy with 
uncompromised safety in patients with dyslipidemia. Safety 
and efficacy have been evaluated in SEACOAST (Safety and 
Efficacy of a combination of Extended Release Niacin and 
Simvastatin trial) and OCEAN (Open label Evaluation of 
the safety and Efficacy of a combination of Niacin ER and 
Simvastatin) trials.36,37 SEACOAST compared the safety and 
efficacy of simvastatin monotherapy with fixed dose combi-
nation of niacin ER and simvastatin in patients with mixed 
dyslipidemia. In SEACOAST-I trial, fixed dose combination 
of niacin ER and simvastatin (1000/20 and 2000/20) showed 
significant dose-related improvements in non-HDL-C, HDL, 
TG, and lipoprotein(a) compared to simvastatin monotherapy. 
The most notable results were the 24% increase in HDL-C, 
38% reduction in TG, and 25% reduction of lipoprotein(a) 
in a group treated with niacin/simvastatin combination.36 
This has been further demonstrated in SEACOAST-II trial, 
which showed a 17.1% reduction in primary end point of 
non-HDL-C with niacin/simvastatin 2000/40 compared to 
a 10.1% reduction in simvastatin 80 mg monotherapy. The 
OCEAN trial was a randomized, open label, multicenter 
study which evaluated the safety and efficacy of a fixed 
dose combination of niacin and simvastatin in patients with 
elevated non-HDL.37 The primary end point was long-term 
safety and secondary endpoints were the serum levels of 
non-HDL-C, IDL-C, and TG. In the subgroup of patients 
who failed to reach their goals with simvastatin as baseline 
therapy, 82% achieved non-HDL goals, 85% reached HDL 
goals, 67% reached HDL goals, and 64% reached TG target 
(65% reached all combined goals).37
Another excellent clinical outcome trial (HATS) demon-
strated efficacy of the combination treatment with niacin and 
simvastatin. This trial, the HDL-Atherosclerosis Treatment 
Study (HATS) was a double-blind, placebo-controlled trial in 
which 160 patients with low HDL and low LDL  145 mg/dL 
were enrolled. Coronary angiography was done at baseline 
and 2-year follow up and the endpoints were the angiographic 
change in CAD and occurrence of first cardiovascular event 
such as MI, death, coronary revascularization, and stroke. 
There was a slight progression of angiographic CAD in the 
placebo group (3.9% changes) and regression of angiographic 
CAD (0.4% change) in the treatment group with niacin 
and simvastatin. The authors concluded that treatment with 
niacin/simvastatin in CAD patients with low HDL resulted 
in slight regression of atherosclerosis but translated into 90% 
reduction in clinical events over a 3-year period.38
Furthermore, the Arterial Biology for the Investigation of 
the Treatment Effects of Reducing cholesterol (ARBITER) 
evaluated effects of niacin ER added to background of statin 
therapy.39 This was a double-blind, placebo-controlled study 
of once-daily niacin ER 1000 mg added to background 
statin therapy in 167 patients with known CAD with low 
HDL-C levels. The primary end point was change in carotid 
intima-media thickness (CIMT) after 12 months. The change 
in CIMT was 0.044 mm in the placebo group compared to 
0.023 mm in the niacin group. The subgroup analysis of this 
study also showed that statin-treated patient had a similar 
CIMT progression regardless of insulin resistance status. 
One hundred thiry patients of ARBITER-2 who completed 
the blinded 12 months study end point were followed for 
an additional 12 months on open label as a prespecified 
extension study of ARBITER-2, called ARBITER-3.40 The 
patients in ARBITER-3 included patients from ARBITER-2 
who were on combination of niacin/statin and continued on 
the same regimen and for total of 2-year period. This also 
included patients from ARBITER-2 who were initially on 
statin and were switched to niacin/statin and followed for an 
additional 12 months. There was a significant regression of 
atherosclerosis as measured by CIMT at both 12 months and 
24 months compared to statin therapy alone.40 Discussion on 
niacin would be incomplete without mentioning its common 
side effect, flushing. Such flushing is initially seen in 80% 
patients and disappears over period of time. Recent data 
have suggested that flushing may be a marker of high lipid 
response to niacin therapy.41 This was assessed in subgroup 
analysis of 77 patients in ARBITER-2. Interestingly, patients 
who reported flushing had a significantly greater response 
to increase in HDL-C than those patients without flushing. 
If these results are confirmed in larger trials, patients may be 
convinced that flushing is less of a nuisance and will therefore 
adhere to niacin treatment.Vascular Health and Risk Management 2009:5 797
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Fibrates and fenofibrates
Several studies have shown the cardiovascular benefits of 
fibrate therapy. The Helsinki Heart Study (HHS)42 showed a 
71% reduction in CHD in patients taking gemfibrozil compared 
to patients receiving placebo, and similar results were seen 
in VA-HIT (Veterans Affairs-High density lipoprotein 
Intervention Trial)37 which showed a 41% reduction in CHD 
and stroke with gemfibrozil compared to placebo in a subgroup 
of patients with DM. The BIP trial43 (Bezafibrate Infarction 
Prevention) evaluated the long-term cardiovascular benefit 
of bezafibrate therapy. This study demonstrated significant 
long-term cardiovascular protection which was attenuated by 
unbalanced use of non-study lipid-lowering drugs.
Fibrates work by activating peroxisome proliferator-
activated (PPRA) alpha receptors which modulate several 
aspects of lipid metabolism by increasing expression of APO 
A-1, APO-11, and ABCA1, and lowering expression of APO 
C-111. They also increase HDL-C particles. Fibrates increase 
LPL synthesis which clears VLDL clearance and lowers TG. 
They also increase B-oxidation of fatty acids leading to a 
decrease in TG and VLDL production.44,45
Fenofibrate therapy was tested in FIELD (Fenofibrate 
Intervention and Event Lowering in Diabetes) trial.46 This 
study was planned to extend the findings of the HHS and 
VA-HIT studies by investigating the long-term effect of 
fenofibrates in the largest trial of patients (total 9795) with 
type 2 DM with a 5-year follow up. The fenofibrates showed 
a 11% reduction (insignificant) in primary end point of CHD 
but the study did show a 24% reduction in non-fatal MI and 
a 21% reduction in coronary revascularization (significant). 
The interesting aspects of this study were certain prespecified 
tertiary endpoints like effects on microvascular complication 
of DM such as microalbuminuria, diabetic retinopathy, 
and amputation due to non-traumatic causes. In the overall 
analysis for prespecified endpoints, there was a regression 
of microalbuminuria in the fenofibrate group.46 There 
was also a beneficial effect in the subgroup with diabetic 
retinopathy. The fenofibrate group showed a 31% reduction 
in the need for first laser treatment compared to placebo, and 
benefits progressively increased thereafter.47 Fenofibrates 
also reduced the number needing non-traumatic amputation 
in these diabetes patients. This demonstrates the beneficial 
effects of fenofibrate in preventing macro- and microvascular 
complications of DM.
Combination of fibrates and statins
As fibrates modify all aspects of dyslipidemia, their use in 
combination with statins is very attractive.48 Both agents 
have the potential for myopathy and the risk of adverse 
events depends on the pharmacokinetic interaction between 
their affects on statin metabolism and clearance.49–53 Several 
studies have shown that gemfibrozil interferes with the 
metabolism of statins by inhibiting glucoronidation. This 
possibly can raise statin levels, predisposing the patients to 
myopathy.48,49 In contrast, fenofibrate does not interfere with 
statin metabolism and therefore may be safer to use in combi-
nation with statin therapy.49 Because of this pharmacokinetic 
interaction, the National Lipid association (NLA) safety task 
force has recommended avoidance of usage of gemfibrozil in 
combination with statins, and fenofibrates may be the preferred 
fibrate to use in combination with statins.54 It has been also 
stated in NCEP ATP-III update in 2004 that, unlike gemfibrozil, 
fenofibrates does not increase rate of myositis when used in 
conjunction with moderate doses of statins.55 There are several 
ongoing trials to address this issue of combination therapy of 
omega-3 fatty acids, niacin, fibrates, and statins.56,57
Other drugs on the horizon
CeTP inhibitors
The action of CETP plays an important role in determining 
the size and blood levels of HDL particles. Low HDL-C 
level constitutes a major risk factor for CHD. In view of 
lack of effective therapeutic intervention for low HDL-C, 
CETP inhibition offered a very attractive strategy to raise 
HDL-C. A CETP inhibitor was investigated in a trial in which 
torcetrapib markedly increased HDL-C levels as monotherapy 
as well as in combination with a statin.58 Unfortunately its 
development was halted in phase III trial in 2006 due an 
increase in all-cause mortality in the treatment group with 
monotherapy or in combination with atorvastatin.
Apo A-1 Milano
Apo A-1 Milano is a naturally occurring mutated variant of 
the Apo A-1 found in human HDL. Apo A-1 Milano mutation 
was discovered by accident, present in 3.5% of the population 
of small village in Italy, Limone sul Garda. These carriers 
were found to have significantly reduced cardiovascular 
disease despite low HDL and high TG. Clinical trials with 
recombinant Apo A-1 Milano published in JAMA59 showed 
a significant regression of coronary atherosclerosis as 
measured by intravascular ultrasound. Although promising, 
these results require confirmation in larger trials.
Conclusion
Large trials have consistently shown a significant benefit of 
LDL-C intervention but there is a significant residual risk Vascular Health and Risk Management 2009:5 798
Sharma et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
for cardiovascular events especially in high-risk patients with 
DM. This residual risk is predominantly due to low HDL-C 
and increased TG. NCEP has suggested the use of niacin 
or a fibrate as an addional agent for mixed dyslipidemia. 
Ongoing trials will be needed to demonstrate the incremental 
cardiovascular disease benefits and safety of combination 
regimens.
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